Literature DB >> 32822115

A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 2 - Application to Current Therapies in Crohn's Disease.

Katharine V Rogers1, Steven W Martin2, Indranil Bhattacharya3, Ravi Shankar Prasad Singh4, Satyaprakash Nayak2.   

Abstract

Inflammatory bowel disease (IBD) is a heterogeneic disease with a variety of treatments targeting different mechanisms. A multistate, mechanistic, mathematical model of IBD was developed in part 1 of this two-part article series. In this paper, application of the model to predict response of key clinical biomarkers following different treatment options for Crohn's disease was explored. Five therapies, representing four different mechanisms of action, were simulated in the model and longitudinal profiles of key clinical markers, C-reactive protein and fecal calprotectin were compared with clinical observations. Model simulations provided an accurate match with both central tendency and variability observed in biomarker profiles. We also applied the model to predict biomarker and clinical response in an experimental, combination therapy of existing therapeutic options and provide possible mechanistic basis for the increased response. Overall, we present a validated, modular, mechanistic model construct, which can be applied to explore key biomarkers and clinical outcomes in IBD.
© 2020 Pfizer Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Year:  2020        PMID: 32822115      PMCID: PMC7877864          DOI: 10.1111/cts.12850

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  24 in total

Review 1.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors:  Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

2.  Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.

Authors:  Matthias Jürgens; Jestinah M Mahachie John; Isabelle Cleynen; Fabian Schnitzler; Herma Fidder; Wouter van Moerkercke; Vera Ballet; Maja Noman; Ilse Hoffman; Gert van Assche; Paul J Rutgeerts; Kristel van Steen; Severine Vermeire
Journal:  Clin Gastroenterol Hepatol       Date:  2011-02-17       Impact factor: 11.382

3.  Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Authors:  Bruce E Sands; Jingjing Chen; Brian G Feagan; Mark Penney; William A Rees; Silvio Danese; Peter D R Higgins; Paul Newbold; Raffaella Faggioni; Kaushik Patra; Jing Li; Paul Klekotka; Chris Morehouse; Erik Pulkstenis; Jörn Drappa; René van der Merwe; Robert A Gasser
Journal:  Gastroenterology       Date:  2017-04-05       Impact factor: 22.682

4.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

5.  A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development.

Authors:  G Dwivedi; L Fitz; M Hegen; S W Martin; J Harrold; A Heatherington; C Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-08

Review 6.  Fecal calprotectin in inflammatory bowel disease.

Authors:  Natalie E Walsham; Roy A Sherwood
Journal:  Clin Exp Gastroenterol       Date:  2016-01-28

7.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment?

Authors:  M C Peterson; M M Riggs
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-12

8.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Authors:  Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire
Journal:  Gut       Date:  2014-01-28       Impact factor: 23.059

9.  Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.

Authors:  Giulia Roda; Bindia Jharap; Narula Neeraj; Jean-Frederic Colombel
Journal:  Clin Transl Gastroenterol       Date:  2016-01-07       Impact factor: 4.488

10.  Know Your Variability: Challenges in Mechanistic Modeling of Inflammatory Response in Inflammatory Bowel Disease (IBD).

Authors:  Katharine V Rogers; Indranil Bhattacharya; Steven W Martin; Satyaprakash Nayak
Journal:  Clin Transl Sci       Date:  2017-10-06       Impact factor: 4.689

View more
  4 in total

Review 1.  Recent applications of quantitative systems pharmacology and machine learning models across diseases.

Authors:  Sara Sadat Aghamiri; Rada Amin; Tomáš Helikar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-20       Impact factor: 2.410

2.  Predictive approaches in inflammatory bowel disease.

Authors:  Philippe Pinton
Journal:  Clin Transl Sci       Date:  2021-10-30       Impact factor: 4.689

Review 3.  Computational models in inflammatory bowel disease.

Authors:  Philippe Pinton
Journal:  Clin Transl Sci       Date:  2022-02-05       Impact factor: 4.689

4.  A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing.

Authors:  Sai Phanindra Venkatapurapu; Ryuichi Iwakiri; Eri Udagawa; Nikhil Patidar; Zhen Qi; Ryoko Takayama; Kei Kumar; Yuki Sato; Marcelo Behar; Patrick Offner; Gaurav Dwivedi; Haruna Miyasaka; Ryohsuke Ken Suzuki; Anna Lissa Hamada; Paul M D'Alessandro; Jovelle Fernandez
Journal:  Adv Ther       Date:  2022-05-17       Impact factor: 4.070

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.